QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, August 25, 2004, 24(34):7464-7476; doi:10.1523/JNEUROSCI.0612-04.2004

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (13) Citing Articles via Google Scholar Google Scholar Articles by Rajadhyaksha, A. Articles by Kosofsky, B. E. Search for Related Content PubMed PubMed Citation Articles by Rajadhyaksha, A. Articles by Kosofsky, B. E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB AMPHETAMINE

 Previous Article  |  Next Article 

Behavioral/Systems/Cognitive
L-Type Ca²⁺ Channels Mediate Adaptation of Extracellular Signal-Regulated Kinase 1/2 Phosphorylation in the Ventral Tegmental Area after Chronic Amphetamine Treatment

Anjali Rajadhyaksha,¹ Isabelle Husson,² Shirish S. Satpute,¹ Karsten D. Küppenbender,² J. Q. Ren,² Rejean M. Guerriero,² David G. Standaert,² and Barry E. Kosofsky²

¹NMR Center, Department of Radiology, and ²Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129

L-type Ca²⁺ channels (LTCCs) play an important role in chronic psychostimulant-induced behaviors. However, the Ca²⁺ second messenger pathways activated by LTCCs after acute and recurrent psychostimulant administration that contribute to drug-induced molecular adaptations are poorly understood. Using a chronic amphetamine treatment paradigm in rats, we have examined the role of LTCCs in activating the mitogen-activated protein (MAP) kinase pathway in the ventral tegmental area (VTA), a primary target for the reinforcing properties of psychostimulants. Using immunoblot and immunohistochemical analyses, we find that in chronic saline-treated rats a challenge injection of amphetamine increases phosphorylation of MAP [extracellular signal-regulated kinase 1/2 (ERK1/2)] kinase in the VTA that is independent of LTCCs. However, in chronic amphetamine-treated rats there is no increase in amphetamine-mediated ERK1/2 phosphorylation unless LTCCs are blocked, in which case there is robust phosphorylation in VTA dopamine neurons. Examination of the expression of phosphatases reveals an increase in calcineurin [protein phosphatase 2B (PP2B)] and MAP kinase phosphatase-1 (MKP-1) in the VTA. Using in situ hybridization histochemistry and immunoblot analyses, we further examined the mRNA and protein expression of the LTCC subtypes Ca_v1.2 and Ca_v1.3 in VTA dopamine neurons in drug-naive animals and in rats after chronic amphetamine treatment. We found an increase in Ca_v1.2 mRNA and protein levels, with no change in Ca_v1.3. Together, our results suggest that one aspect of LTCC-induced changes in second messenger pathways after chronic amphetamine exposure involves activation of the MAP kinase phosphatase pathway by upregulation of Ca_v1.2 in VTA dopaminergic neurons.

Key words: amphetamine; L-type Ca²⁺ channels; VTA; ERK1/2 phosphorylation; Ca_v1.2; addiction

---

Received Feb 20, 2004; revised June 18, 2004; accepted July 6, 2004.

This article has been cited by other articles:

				E. Valjent, A.-G. Corbille, J. Bertran-Gonzalez, D. Herve, and J.-A. Girault Inhibition of ERK pathway or protein synthesis during reexposure to drugs of abuse erases previously learned place preference PNAS, February 21, 2006; 103(8): 2932 - 2937. [Abstract] [Full Text] [PDF]

				A. M. Rajadhyaksha and B. E. Kosofsky Psychostimulants, L-type Calcium Channels, Kinases, and Phosphatases Neuroscientist, October 1, 2005; 11(5): 494 - 502. [Abstract] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help